Modality diversification and best-in-class small-molecule drugs: Recent trend of orphan drug development
Only 5% of orphan diseases have approved drugs, leading to a high demand for new treatment. As a result, pharmaceutical companies have shifted their focus of drug development to orphan diseases. This study conducted a database search to analyze the modality and development strategy of orphan drugs a...
Main Author: | Ryo Okuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Medicine in Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098623000064 |
Similar Items
-
Top Selling (2026) Small Molecule Orphan Drugs: A Journey into Their Chemistry
by: Davide Benedetto Tiz, et al.
Published: (2023-01-01) -
Orphan drug: Development trends and strategies
by: Aarti Sharma, et al.
Published: (2010-01-01) -
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01) -
Disentangling the Cost of Orphan Drugs Marketed in the United States
by: Hana Althobaiti, et al.
Published: (2023-02-01) -
Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)